Zhengye Biotechnology Holding Ltd
Close on Oct 19, 2026
About Zhengye Biotechnology
Pharmaceutical Preparations, SIC 2834
Zhengye Biotechnology Holding Limited is an animal healthcare company that develops, manufactures, and sells veterinary biologics. Operating through its operating subsidiaries in China, the company provides veterinary products and health solutions designed for livestock and food-producing animals. Its primary customer base consists of agricultural operators, commercial livestock producers, and farming entities seeking veterinary healthcare products to prevent animal diseases and maintain herd welfare.
The company concentrates substantially all of its business activities and physical facilities within the People's Republic of China, with supplementary corporate subsidiary presence in Hong Kong. Its principal executive offices and operational headquarters are situated in Jilin City, Jilin Province, China.
Summary of the business section of Zhengye Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zhengye Biotechnology Holding Ltd
- Headquarters
- Jilin, China
- Address
- No.1 Lianmeng Street, Jilin Economic &, Technical Development Zone
- Phone
- 86-13844801919
- Employees
- 51, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- F4
- Auditor
- WWC, P.C., San Mateo, California
Stock & identifiers
- Ticker
- ZYBT
- Exchange
- Nasdaq
- IPO date
- Jan 7, 2025
- Shares outstanding
- 47M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1975641
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Songlin Song | Co-Chief Executive Officer | – |
| Yuhong (nmn) Cheng | Vice General Manager | – |
| Ping (nmn) Wang | Chief Financial Officer | – |
| Aiden Han | Co-Chief Executive Officer | – |
| Wei Lian | Vice General Manager | – |
| Zhongyao Liu | Chief Operating Officer | – |
| Ping (PiJi) Jiang | Director | – |
| Zhenfa Han | Director | 42,963,748 |
| Qiyi Hu | Director | – |
| Guohan (nmn) Li | Director | – |
| Wenhua Sun | Director | – |
Employees
Headcount reported in annual reports
“As of the date of this annual report, the operating entity has a total of 51 employees in the R&D department.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 29, 2025 | Late filing | Notification of late filing |
| Jan 7, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 19, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |